文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

用于程序性细胞死亡的杂交纳米PROTAC对HER2蛋白的持续降解

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death.

作者信息

Wang Zhihang, Tan Mixiao, Su Wen, Huang Wenping, Zhang Jie, Jia Fuhao, Cao Guoliang, Liu Xinyang, Song Haohao, Ran Haitao, Nie Guangjun, Wang Hai

机构信息

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.

University of Chinese Academy of Sciences, Beijing 100049, China.

出版信息

J Med Chem. 2023 May 11;66(9):6263-6273. doi: 10.1021/acs.jmedchem.3c00013. Epub 2023 Apr 24.


DOI:10.1021/acs.jmedchem.3c00013
PMID:37092695
Abstract

Proteolysis-targeting chimera (PROTAC) has emerged as a promising strategy for degrading proteins of interest. Peptide-based PROTACs offer several advantages over small-molecule-based PROTACs, such as high specificity, low toxicity, and large protein-protein interaction surfaces. However, peptide-based PROTACs have several intrinsic shortcomings that strongly limit their application including poor cell permeability and low stability and potency. Herein, we designed a nanosized hybrid PROTAC (GNCTACs) to target and degrade human epidermal growth factor receptor 2 (HER2) in tumor cells. Gold nanoclusters (GNCs) were utilized to connect HER2-targeting peptides and cereblon (CRBN)-targeting ligands. GNCTACs could overcome the intrinsic barriers of peptide-based PROTACs, efficiently delivering HER2-targeting peptides in the cytoplasm and protecting them from degradation. Furthermore, a fasting-mimicking diet was applied to enhance the cellular uptake and proteasome activity. Consequently, more than 95% of HER2 in SKBR3 cells was degraded by GNCTACs, and the degradation lasted for at least 72 h, showing a catalytic-like reaction.

摘要

蛋白酶靶向嵌合体(PROTAC)已成为一种有前景的降解目标蛋白的策略。基于肽的PROTAC比基于小分子的PROTAC具有多个优势,如高特异性、低毒性以及大的蛋白质-蛋白质相互作用表面。然而,基于肽的PROTAC存在一些固有缺点,严重限制了它们的应用,包括细胞通透性差、稳定性低和效力低。在此,我们设计了一种纳米级混合PROTAC(GNCTACs),以靶向并降解肿瘤细胞中的人表皮生长因子受体2(HER2)。利用金纳米簇(GNCs)连接靶向HER2的肽和靶向大脑神经酰胺酶(CRBN)的配体。GNCTACs可以克服基于肽的PROTAC的固有障碍,在细胞质中有效递送靶向HER2的肽并保护它们不被降解。此外,采用模拟禁食饮食来增强细胞摄取和蛋白酶体活性。因此,SKBR3细胞中超过95%的HER2被GNCTACs降解,且降解持续至少72小时,呈现出类似催化反应的效果。

相似文献

[1]
Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death.

J Med Chem. 2023-5-11

[2]
Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.

Bioorg Chem. 2024-4

[3]
Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.

Bioorg Med Chem. 2023-3-15

[4]
PROTACS: A technology with a gold rush-like atmosphere.

Eur J Med Chem. 2023-2-5

[5]
Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy.

Angew Chem Int Ed Engl. 2023-3-6

[6]
Discovery of E3 Ligase Ligands for Target Protein Degradation.

Molecules. 2022-10-2

[7]
IKZF2 Degradation: It's Time to Take into Account it When Designing Cereblon-Based PROTACs.

Chembiochem. 2024-8-19

[8]
CRBN ligand expansion for hematopoietic prostaglandin D synthase (H-PGDS) targeting PROTAC design and their in vitro ADME profiles.

Bioorg Med Chem. 2023-4-15

[9]
In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.

Biomaterials. 2023-4

[10]
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity.

Eur J Med Chem. 2024-3-15

引用本文的文献

[1]
Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy.

Pharmaceutics. 2025-8-10

[2]
Proximity-induced membrane protein degradation for cancer therapies.

RSC Med Chem. 2025-5-2

[3]
Nanoparticle-Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology.

Angew Chem Int Ed Engl. 2025-5-5

[4]
Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients.

Biomark Res. 2025-1-9

[5]
Aberrant Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions.

Cells. 2024-1-25

[6]
Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

Angew Chem Int Ed Engl. 2024-1-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索